Key facts
- It has raised $8.4M across 4 recorded rounds; the latest was Buyout/LBO (Add-on)† in Dec 2020.
- Oncopia Therapeutics has filed 3 Form Ds with the SEC since 2018, most recently Jan 2019 ($1.5M sold to 2 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Oncopia Therapeutics
Create free account
No card required
Funding rounds
4 roundsDec 2020Buyout/LBO (Add-on)†—▮
About Oncopia Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Oncopia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Oncopia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Oncopia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.